Articles by Katie Anderson

41. 9 Drugs Granted Fast Track By FDA's Voucher Program 10/23/2025

    With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.

42. Leaders In The Excipient Market: Region And Type 10/21/2025

    Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.

43. 3 [Potential] Solutions To A More Resilient Supply Chain 10/16/2025

    In her opening presentation, Harney noted that there were 98 drug shortages in 2024, 40 medicines in shortage for over three years, and the average duration of a shortage has increased from three years to four years.

44. Extreme Weather Is Testing Pharma's Resilience — Is It Ready? 10/14/2025

    It may sound like a stretch, but researchers from Harvard University showed how a disproportionate amount of pharmaceutical manufacturers are in areas of climate-driven extreme weather events. Is the pharmaceutical industry currently set up to withstand them?  

45. Eco-Friendly HBL: Cheaper, Cleaner, And Ready For Pharma 10/6/2025

    Researchers at the University of Maine may have found a way to do two out of three by developing a new method of producing (S)-3-hydroxy-γ-butyrolactone (HBL) for statins, HIV inhibitors and antibiotics that can lower their production cost with an added benefit of reducing their carbon footprint.

46. Roll Call In The Oral GLP-1 Race 9/26/2025

    The market for GLP-1 agonists is booming and expected to only get bigger. As rates for obesity and cardiovascular disease increase, so too does the demand for GLP-1 drugs.

47. Pfizer Strengthens Obesity Foothold With Metsera Acquisition 9/22/2025

    After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.

48. From Lab to Plant: Managing Operational Environment During Scale-Up 9/18/2025

    Though these challenges can result from equipment, raw material differences, and process variability, operational environments must be a major focus during lab trials, as Yuhei Yamamoto and his team at Takeda learned in a recent experience.

49. FDA Cracks Down On GLP-1 Imports 9/11/2025

    GLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.

50. Oregon Court Upholds Drug Price Transparency Law 9/9/2025

    The law was first enacted in 2018, followed by a lawsuit by Pharmaceutical Research and Manufacturers of America (PhRMA) in 2019, claiming an infringement of free speech for pharmaceutical companies and violation of public property. PhRMA asked the court to bar Oregon from enforcing the law.